HealthyPhase 1NCT01181726

Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions

A Phase 1 study testing Estradiol/Norethindrone acetate and Activella® in people with Healthy, run by Teva Pharmaceuticals USA at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The objective of this study was to determine and compare the rate and extent of absorption of norethindrone and unconjugated estradiol from a test formulation of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg versus the reference Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets under fed… Read more about this study

Who is it for?: Ages 18 to 65 years, women onlyHealthy volunteers can take part
Conditions the study is for: Healthy
What is being tested?: Estradiol/Norethindrone acetate and Activella®
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 40 participants
Where: 1 siteCanada
Study dates: Jan 2007to Feb 2007
Phase: Phase 1
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 65 years
Women only
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

Non-smoking or smoking (up to 10 cigarettes/day), physiologically or surgically post-menopausal female within the age range of 18-65 years.
17β-estradiol serum levels of ≤ 92 pmol/L and follicle-stimulating hormone (FSH) of ≥ 40 IU/L.
Body Mass Index (BMI) greater than or equal to 19.0 kg/m2 and less than or equal to 30.0 kg/m2.
Normal findings in the physical examination, 12-lead electrocardiogram (ECG) and vital signs.
Hemoglobin ≥ 115 g/L.
Normal pap smear.

Show all 13Show fewer

Normal mammogram within 1 year for subjects who are over the age of 50 years.
Negative for drugs of abuse and alcohol.
Negative for hepatitis B-surface antigen, hepatitis C, and Human Immunodeficiency Virus (HIV).
No clinical laboratory values outside the acceptable range unless the Principal Investigator or Sub-Investigator decides that they are not clinically significant (NCS).
Negative for pregnancy.
Subjects who are surgically post-menopausal with an intact uterus (i.e. bilateral oophorectomy) for at least 6 months, or physiologically post-menopausal (i.e. spontaneous amenorrhea) for at least 1 year, and who will adhere to contraceptive requirements from at least 10 days before Period I check-in, during the study and up until 1 month after the end of the study.
Availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements, as evidenced by a signed ICF.

Who cannot join

Known history of hypersensitivity to norethindrone and estradiol combinations and/or norethindrone, and/or estradiol.
Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, or hematological diseases, malignancies, or migraines, unless deemed not clinically significant by the Principal Investigator or Sub-Investigator.
Known history of liver, kidney, and/or gallbladder dysfunction/disease, chronic diarrhea, or inflammatory bowel diseases.
Known history or presence of cerebrovascular diseases or venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.
Any history of stroke.
Presence of any significant physical or organ abnormality.

Show all 28Show fewer

History of osteoporosis.
History or presence of fibrocystic breast disease.
History or presence of breast, endometrial, cervical, and/or uterine carcinoma.
Any illness during the 4 weeks before this study, unless deemed not clinically significant by the Principal Investigator or Sub-Investigator.
Any history or evidence of psychiatric or psychological disease, unless deemed not clinically significant by the Principal Investigator or the Sub-Investigator.
Any history or abnormal vaginal bleeding, unless deemed not clinically significant by the Principal Investigator or the Sub-Investigator.
Any history of asthma (after 12 years of age).
Evidence of pregnancy or lactation.
Any history of severe allergic reaction (including drugs, food, insect bites, environmental allergens).
Known history or presence of food allergies, or any condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
Any history or drug abuse.
Any recent history of alcohol abuse (less than 1 year).
Use of any prescription medication within 30 days preceding this study.
Use of hormone replacement therapy within 30 days before drug administration.
Use of over-the-counter (OTC) medication or any herbal supplement within the 7 days preceding this study.
Use of hormonal contraceptives, oral, transdermal, implant within 30 days before drug administration or a depot injection or progestogen drug within 1 year before the drug administration.
Depot injection of any drug within 6 months.
Blood draws within 56 days preceding this study, during the conduct of any clinical study at another facility, or within the lockout period specified by previous study.
Blood donations within 56 days preceding this study.
Participation as a plasma donor in a plasmapheresis program within 7 days preceding this study.
Participation in a clinical trial with an investigational drug within 30 days preceding this study.
Intolerance to venipuncture.

Trial locations and contacts

1 site in 1 country.

Canada1 site

Biovail Contract Research
Toronto, Ontario, M1L 4S4

Other trials in Canada

About this study

Official title: A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg Versus Activella® (1 mg Estradiol/0.5 mg Norethindrone Acetate) Tablets in Normal, Healthy, Post-Menopausal Female Subjects.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA Bioequivalence Statistical Methods

Conditions: Healthy
Being tested: Estradiol/Norethindrone acetate, Activella®
Keywords: Bioequivalence, Healthy Subjects

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Estradiol/Norethindrone acetateDrug
Also called Mimvey®
1 mg/0.5 mg Tablets
Activella®Drug
Also called Estradiol/Norethindrone acetate (generic name)
1 mg/0.5 mg Tablets

Study groups in NCT01181726
Study group	Role	What they receive
Investigational Test Product	Experimental	Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg Receives: Drug: Estradiol/Norethindrone acetate
Reference Listed Drug	Active comparator	Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets Receives: Drug: Activella®

What is being measured

The primary outcome is the main question the study is designed to answer.

Cmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma)
Bioequivalence based on Norethindrone Cmax.
Measured: Blood samples collected over a 36 hour period.
AUC0-t of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Bioequivalence based on Norethindrone AUC0-t.
Measured: Blood samples collected over a 36 hour period.
AUC0-inf of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
Bioequivalence based on Norethindrone AUC0-inf.
Measured: Blood samples collected over a 36 hour period.
Cmax of Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
Bioequivalence based on Corrected Total Estrone Cmax.
Measured: Blood samples collected over a 72 hour period.
AUC0-t of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Bioequivalence based on Corrected Total Estrone AUC0-t.
Measured: Blood samples collected over a 72 hour period.
AUC0-inf of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
Bioequivalence based on Corrected Total Estrone AUC0-inf.
Measured: Blood samples collected over a 72 hour period.

Secondary outcomes (15)

Cmax of Uncorrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
Informational comparison of Cmax values for Uncorrected Total Estrone.
Measured: Blood samples collected over a 72 hour period.
AUC0-t of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Informational comparison of AUC0-t values for Uncorrected Total Estrone.
Measured: Blood samples collected over a 72 hour period.
AUC0-inf of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
Informational comparison of AUC0-inf values for Uncorrected Total Estrone.
Measured: Blood samples collected over a 72 hour period.
Cmax of Uncorrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
Informational comparison of Cmax values for Uncorrected Unconjugated Estradiol.
Measured: Blood samples collected over a 72 hour period.
AUC0-t of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Informational comparison of AUC0-t values for Uncorrected Unconjugated Estradiol.
Measured: Blood samples collected over a 72 hour period.
AUC0-inf of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
Informational comparison of AUC0-inf values for Uncorrected Unconjugated Estradiol.
Measured: Blood samples collected over a 72 hour period.
Cmax of Uncorrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
Informational comparison of Cmax values for Uncorrected Unconjugated Estrone.
Measured: Blood samples collected over a 72 hour period.
AUC0-t of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Informational comparison of AUC0-t values for Uncorrected Unconjugated Estrone.
Measured: Blood samples collected over a 72 hour period.
AUC0-inf of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
Informational comparison of AUC0-inf values for Uncorrected Unconjugated Estrone.
Measured: Blood samples collected over a 72 hour period.
Cmax of Corrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
Informational comparison of Cmax values for Corrected Unconjugated Estradiol.
Measured: Blood samples collected over a 72 hour period.
AUC0-t of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Informational comparison of AUC0-t values for Corrected Unconjugated Estradiol.
Measured: Blood samples collected over a 72 hour period.
AUC0-inf of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
Informational comparison of AUC0-inf values for Corrected Unconjugated Estradiol.
Measured: Blood samples collected over a 72 hour period.
Cmax of Corrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
Informational comparison of Cmax values for Corrected Unconjugated Estrone.
Measured: Blood samples collected over a 72 hour period.
AUC0-t of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Informational comparison of AUC0-t values for Corrected Unconjugated Estrone.
Measured: Blood samples collected over a 72 hour period.
AUC0-inf of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
Informational comparison of AUC0-inf values for Corrected Unconjugated Estrone.
Measured: Blood samples collected over a 72 hour period.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Jan 2007Feb 2007

First posted13 Aug 2010 (estimated)
Study startJan 2007
Primary completionFeb 2007
Study completionFeb 2007

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for HealthyStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 1
Allocation: Randomised
Intervention model: Crossover
Masking: None (open label)
Enrolment: 40 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT01181726
Sponsor's protocol ID: 3252
Status last verified: Nov 2010
First submitted: 11 Aug 2010
Last updated: 8 Dec 2010
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
RecruitingObservational study
Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making
Healthy Volunteers
Active, not recruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
Healthy
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
Recruiting
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Fatty Acids, Omega-3, Fish Oils

All Healthy trials

Study at a glance

From the registry record, last updated by the sponsor on 8 Dec 2010. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg Versus Activella® (1 mg Estradiol/0.5 mg Norethindrone Acetate) Tablets in Normal, Healthy, Post-Menopausal Female Subjects.
ClinicalTrials.gov ID: NCT01181726
Acronym / sponsor ID: 3252
Conditions: Healthy
Keywords: Bioequivalence, Healthy Subjects
Phase: Phase 1
Study type: Interventional
Recruitment status: Completed
Enrolment: 40 participants (actual)
Lead sponsor: Teva Pharmaceuticals USAIndustry (pharma, biotech, devices)
Study start: Jan 2007
Primary completion: Feb 2007 (actual)
Study completion: Feb 2007 (actual)
First posted: 13 Aug 2010 (estimated)
Results: Posted 7 Oct 2010

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA Bioequivalence Statistical Methods

Study design

Allocation: Randomised
Intervention model: Crossover
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Investigational Test Product	Experimental	Drug: Estradiol/Norethindrone acetateEstradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg
Reference Listed Drug	Active comparator	Drug: Activella®Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets

Who may qualify

Ages: 18 to 65 years
Sex: Female only
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (13 listed)

Non-smoking or smoking (up to 10 cigarettes/day), physiologically or surgically post-menopausal female within the age range of 18-65 years.
17β-estradiol serum levels of ≤ 92 pmol/L and follicle-stimulating hormone (FSH) of ≥ 40 IU/L.
Body Mass Index (BMI) greater than or equal to 19.0 kg/m2 and less than or equal to 30.0 kg/m2.
Normal findings in the physical examination, 12-lead electrocardiogram (ECG) and vital signs.
Hemoglobin ≥ 115 g/L.

Key exclusion criteria (28 listed)

Known history of hypersensitivity to norethindrone and estradiol combinations and/or norethindrone, and/or estradiol.
Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, or hematological diseases, malignancies, or migraines, unless deemed not clinically significant by the Principal Investigator or Sub-Investigator.
Known history of liver, kidney, and/or gallbladder dysfunction/disease, chronic diarrhea, or inflammatory bowel diseases.
Known history or presence of cerebrovascular diseases or venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.
Any history of stroke.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Estradiol/Norethindrone acetateAlso: Mimvey®1 mg/0.5 mg Tablets	Drug	Investigational Test Product
Activella®Also: Estradiol/Norethindrone acetate (generic name)1 mg/0.5 mg Tablets	Drug	Reference Listed Drug

Primary outcome

Cmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma)
Time frame: Blood samples collected over a 36 hour period.
Bioequivalence based on Norethindrone Cmax.
AUC0-t of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Time frame: Blood samples collected over a 36 hour period.
Bioequivalence based on Norethindrone AUC0-t.
AUC0-inf of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
Time frame: Blood samples collected over a 36 hour period.
Bioequivalence based on Norethindrone AUC0-inf.
Cmax of Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
Time frame: Blood samples collected over a 72 hour period.
Bioequivalence based on Corrected Total Estrone Cmax.
AUC0-t of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Time frame: Blood samples collected over a 72 hour period.
Bioequivalence based on Corrected Total Estrone AUC0-t.
AUC0-inf of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
Time frame: Blood samples collected over a 72 hour period.
Bioequivalence based on Corrected Total Estrone AUC0-inf.

15 secondary outcomes

Cmax of Uncorrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
Time frame: Blood samples collected over a 72 hour period.
AUC0-t of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Time frame: Blood samples collected over a 72 hour period.
AUC0-inf of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
Time frame: Blood samples collected over a 72 hour period.
Cmax of Uncorrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
Time frame: Blood samples collected over a 72 hour period.
AUC0-t of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Time frame: Blood samples collected over a 72 hour period.
AUC0-inf of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
Time frame: Blood samples collected over a 72 hour period.
Cmax of Uncorrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
Time frame: Blood samples collected over a 72 hour period.
AUC0-t of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Time frame: Blood samples collected over a 72 hour period.
AUC0-inf of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
Time frame: Blood samples collected over a 72 hour period.
Cmax of Corrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
Time frame: Blood samples collected over a 72 hour period.
AUC0-t of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Time frame: Blood samples collected over a 72 hour period.
AUC0-inf of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
Time frame: Blood samples collected over a 72 hour period.
Cmax of Corrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
Time frame: Blood samples collected over a 72 hour period.
AUC0-t of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Time frame: Blood samples collected over a 72 hour period.
AUC0-inf of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
Time frame: Blood samples collected over a 72 hour period.

Results and safety

Results posted to the registry on 7 Oct 2010, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Estradiol/Norethindrone Acetate (Test) First	20	19
Activella® (Reference) First	20	20

Primary outcome: Cmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma)

Time frame: Blood samples collected over a 36 hour period.. Mean (Standard Deviation). Unit: ng/mL

Measure	Estradiol/Norethindrone Acetate (Test) n = 39	Activella® (Reference) n = 39
Value	6.54 (3.62)	6.06 (2.95)

Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference): Ratio of the T/R geometric mean x 100: 104.66 (90% CI 94.22 to 116.25)

Population analysed: All participants that completed the study had their samples analyzed.

Primary outcome: AUC0-t of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Time frame: Blood samples collected over a 36 hour period.. Mean (Standard Deviation). Unit: ng*h/mL

Measure	Estradiol/Norethindrone Acetate (Test) n = 39	Activella® (Reference) n = 39
Value	45.03 (21.76)	46.13 (21.62)

Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference): Ratio of the T/R geometric mean x 100: 97.4 (90% CI 93.91 to 101.02)

Population analysed: All participants that completed the study had their samples analyzed.

Primary outcome: AUC0-inf of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Time frame: Blood samples collected over a 36 hour period.. Mean (Standard Deviation). Unit: ng*h/mL

Measure	Estradiol/Norethindrone Acetate (Test) n = 39	Activella® (Reference) n = 39
Value	49.55 (23.08)	50.68 (22.78)

Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference): Ratio of the T/R geometric mean x 100: 97.60 (90% CI 94.05 to 101.30)

Population analysed: All participants that completed the study had their samples analyzed.

Primary outcome: Cmax of Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

Time frame: Blood samples collected over a 72 hour period.. Mean (Standard Deviation). Unit: pg/mL

Measure	Estradiol/Norethindrone Acetate (Test) n = 39	Activella® (Reference) n = 39
Value	27076.08 (11600.13)	27240.03 (11610.70)

Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference): Ratio of the T/R geometric mean x 100: 99.35 (90% CI 92.21 to 107.06)

Population analysed: All participants that completed the study had their samples analyzed.

15 secondary outcomes are reported in the full results.

Adverse events

Time frame: Adverse event data was collected over the course of the study, which was approximately 6 weeks in duration.. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Estradiol/Norethindrone Acetate (Test)	0 of 40 (0%)	1 of 40 (2.5%)	Not reported
Activella® (Reference)	0 of 40 (0%)	2 of 40 (5%)	Not reported

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 8 Dec 2010.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.

Related trials for Healthy

Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
RecruitingObservational study
Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making
Healthy Volunteers
Active, not recruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
Healthy
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
Recruiting
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Fatty Acids, Omega-3, Fish Oils

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Paul Y Tam, M.D., F.R.C.P., F.A.C.P. principal investigator

Biovail Clinical Research

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Estradiol/Norethindrone acetate and Activella® in people with Healthy, run by Teva Pharmaceuticals USA at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 28 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Dec 2010. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 7 Oct 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma) (time frame: Blood samples collected over a 36 hour period.). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01181726.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Dec 2010.